The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic
John T
JT
Columbia University College of Dental Medicine, New York City, NY 10032, USA. jtg2@columbia.edu
Black
Dennis M
DM
Lyles
Kenneth W
KW
Reid
David M
DM
Orwoll
Eric
E
McClung
Michael
M
Bucci-Rechtweg
Christina
C
Su
Guoqin
G
D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D001862:Bone Resorption / Q000097:blood; D024042:Collagen Type I / Q000097:blood; D019992:Databases as Topic; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced / Q000453:epidemiology*; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010455:Peptides / Q000097:blood; D010919:Placebos; D015995:Prevalence; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D000077211:Zoledronic Acid
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D007093:Imidazoles; D010455:Peptides; D010919:Placebos; C052929:collagen type I trimeric cross-linked peptide; D000077211:Zoledronic Acid